Jubilant Life Sciences Limited
In Life Sciences we enjoy leadership positions across our key products at a global level. professionally managed by separate management teams.
down JubilantLifeSciences AR
Jubilant Life Sciences Limited
Science Ingredients and Drug Discovery Solutions. Each of these segments is professionally managed by its separate management teams headed by respective
down JLL AnnualReport
Jubilant Life Sciences Limited
15-Jun-2017 Science Ingredients and Drug Discovery Solutions. Each of these segments is professionally managed by its separate management teams headed ...
down JLL AnnualReport
Jubilant Life Sciences Limited
Jubilant Life Sciences Limited professionally managed by separate management teams. ... Pharmaceuticals and Life Science Ingredients segments.
down JubilantLifeSciences AR
Jubilant Life Sciences Limited Annual Report 2019-20
Jubilant Life Sciences Limited Annual Report 2019-20. Board of direCtors as on July 2020. Priyavrat Bhartia. Director. Arjun Shanker Bhartia. Director.
JubilantLifeSciencesAnnualReport
Applying
Jubilant manufactures a range of Life Science chemicals of Acetyl group and holds leadership position in most of them. Acetyls.
jubilant life sciences brochure
JLS_Cover & Back_Final.cdr
Jubilant Life Sciences Limited Annual Report 2014-15. 1. Dr. Ashok Misra Director. Shyamsundar Bang. Executive Director. Shardul S Shroff. Director.
down JLL Annual Report
Untitled
The management team of Jubilant Life Sciences Limited (Jubilant) – an integrated global pharmaceutical and life sciences company will host a conference call
Q FY Concall Invite
Jubilant Life Sciences - Corporate Sustainability Report 2010-11
09-Nov-2010 pharma business as Jubilant Life Sciences business and completed the process of ... The Global Management Team of Jubilant is presented.
down down jll csr
Jubilant Pharmova - Annual Report 2018-19
Jubilant Life Sciences Limited. 2. Board of Directors. S Sridhar. Director. Dr. Ashok Misra. Director. Sushil Kumar Roongta. Director. Sudha Pillai.
JLL AnnualReport
Contents
02Board of Directors
03Senior Leadership Team
04Chairmen's Message
07Management Discussion & Analysis
38Directors' Report
78Report on Corporate Governance
108Business Responsibility Report
118Independent Auditors' Report on
Financial Statements
124Balance Sheet and Statement of
Profit and Loss
126Statement of Changes in Equity
128Cash Flow Statement
130Notes to the Financial Statements
192Independent Auditors' Report on
Consolidated Financial Statements
196Consolidated Balance Sheet and
Consolidated Statement of Profit and Loss
198Consolidated Statement of Changes in Equity
200Consolidated Cash Flow Statement
202Notes to the Consolidated Financial Statements
277Salient Features of Financial Statements
of Subsidiaries/ Associates/Joint Ventures (Form AOC-1) 280Corporate Information
Annual Report 2016-17 Jubilant Life Sciences Limited23Annual Report 2016-17 Jubilant Life Sciences Limited23
S Sridhar
Director
Sudha Pillai
Director
Dr. Ashok Misra
Director
Sushil Kumar Roongta
Director
Pramod Yadav
Whole-time Director
Arjun Shanker Bhartia
Director
Priyavrat Bhartia
Director
Vivek Mehra
Director
Board of
Directors
Shyam S Bhartia
Chairman
Hari S Bhartia
Co-Chairman and
Managing Director
Annual Report 2016-17 Jubilant Life Sciences Limited23Annual Report 2016-17 Jubilant Life Sciences Limited23
Senior
Leadership Team
Shyam S Bhartia
Chairman
Hari S Bhartia
Co-Chairman and
Managing Director
GP Singh
CEOJubilant Pharma
Pramod Yadav
Co-CEO
Life Science Ingredients
Rajesh Srivastava
Co-CEO
Life Science Ingredients
Steven Hutchins
President
Drug Discovery Solutions
R Sankaraiah
Executive Director
Finance
Ajay Khanna
Group Ombudsman
and Chief Strategic & Public AffairsDr. Ashutosh Agarwal
Chief Scientific Officer
Siddhartha Pahwa
Chief of Supply Chain
Dr. Raju Mistry
ChiefHuman Resources
Officer
Dr. Rajesh Kapoor
Chief of Quality
Annual Report 2016-17 Jubilant Life Sciences Limited45Annual Report 2016-17 Jubilant Life Sciences Limited45
Chairmen's Message
Hari S Bhartia
Co-Chairman and Managing Director
Shyam S Bhartia
Chairman
Annual Report 2016-17 Jubilant Life Sciences Limited45Annual Report 2016-17 Jubilant Life Sciences Limited45
Chairmen's Message
Dear Fellow Shareholders,
We are pleased to announce that the Company has reported highest ever revenue and profits in FY 2017. The differentiated business model focusing on Specialty Pharmaceuticals - Injectables has enabled us to deliver exceptional results and build a strong base for growth in Pharmaceuticals. The Company has generated strong operating cash flow, which enabled reduction of debt and is expected to deliver better results going forward. Our focus is to strengthen the balance sheet, invest in strategic opportunities without increasing debt levels and build strong pipeline or products across our businesses. India continues to be the fastest growing economy globally and is expected to grow by 7.2% in FY 2017- 18 as per projections of the International Monetary Fund. This growth is expected to further accelerate to above 8% in the medium term due to implementation of structural reforms, including the transformative GST regime under the current government. According to Evaluate Pharma, the global pharmaceuticals market is expected to grow at 6.3% Compound Annual Growth Rate (CAGR) to US$ 1.12 trillion by 2022. The growth of complex therapeutic areas is projected to outpace the growth of the overall pharmaceutical market, emphasising the importance of increased R&D in the value chain. Global agriculture, on the other hand, has faced some challenges in the last few years but is likely to see a better demand this year for crop protection chemicals in terms of volume as per a report by Federation of IndianChambers of Commerce and Industry (FICCI).
Business Objectives
We are an integrated global pharmaceutical and life sciences Company present across the entire pharmaceutical value chain and take pride in our positioning as one-stop-shop in the glo bal pharmaceutical and life sciences industry, supplying products and services to customers in over100 countries. Our diversified businesses are segmented
in three major verticals namely Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions. Each of these segments is professionally managed by its separate management teams headed by respective CEOs. As a responsible corporate citizen, we are committed to safeguarding the environment and maintaining a triple bottom line approach of sustainability through delivering a high social, environmental and economic performance. The Pharmaceuticals segment is engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile and Non Sterile products through 6 US FDA approved facilities in India, US and Canada. Our success in this segment is based on several key strengths including an innovative productportfolio in specialty injectables with high entry barriers and limited competition, strong R&D capabilities to back
a differentiated pipeline of products, global competitive edge due to low cost from vertically integrated operations, market leadership in key products and business segments, de-risked business model with low concentration risk and a consistent track record of regulatory approvals. As of March 31, 2017, the Company has a total of 922 filings across geographies. Of this, 710 filings have been approved while 212 filings are pending approval.The Life
Science Ingredients segment is engaged in
Specialty Intermediates, Nutritional Products and Life Science Chemicals through 5 manufacturing facilities in India. In this segment, our strength lies in our integrated business model, strong capabilities in chemistry, low cost of manufacturing through best in class processes and leadership position in key products on a global level. The Drug Discovery Solutions segment provides proprietary in-house innovation for out-licensing purposes and collaborative research and partnership for Drug Discovery through 3 world class research centers in India and US.Performance Review
Contents
02Board of Directors
03Senior Leadership Team
04Chairmen's Message
07Management Discussion & Analysis
38Directors' Report
78Report on Corporate Governance
108Business Responsibility Report
118Independent Auditors' Report on
Financial Statements
124Balance Sheet and Statement of
Profit and Loss
126Statement of Changes in Equity
128Cash Flow Statement
130Notes to the Financial Statements
192Independent Auditors' Report on
Consolidated Financial Statements
196Consolidated Balance Sheet and
Consolidated Statement of Profit and Loss
198Consolidated Statement of Changes in Equity
200Consolidated Cash Flow Statement
202Notes to the Consolidated Financial Statements
277Salient Features of Financial Statements
of Subsidiaries/ Associates/Joint Ventures (Form AOC-1) 280Corporate Information
Annual Report 2016-17 Jubilant Life Sciences Limited23Annual Report 2016-17 Jubilant Life Sciences Limited23
S Sridhar
Director
Sudha Pillai
Director
Dr. Ashok Misra
Director
Sushil Kumar Roongta
Director
Pramod Yadav
Whole-time Director
Arjun Shanker Bhartia
Director
Priyavrat Bhartia
Director
Vivek Mehra
Director
Board of
Directors
Shyam S Bhartia
Chairman
Hari S Bhartia
Co-Chairman and
Managing Director
Annual Report 2016-17 Jubilant Life Sciences Limited23Annual Report 2016-17 Jubilant Life Sciences Limited23
Senior
Leadership Team
Shyam S Bhartia
Chairman
Hari S Bhartia
Co-Chairman and
Managing Director
GP Singh
CEOJubilant Pharma
Pramod Yadav
Co-CEO
Life Science Ingredients
Rajesh Srivastava
Co-CEO
Life Science Ingredients
Steven Hutchins
President
Drug Discovery Solutions
R Sankaraiah
Executive Director
Finance
Ajay Khanna
Group Ombudsman
and Chief Strategic & Public AffairsDr. Ashutosh Agarwal
Chief Scientific Officer
Siddhartha Pahwa
Chief of Supply Chain
Dr. Raju Mistry
ChiefHuman Resources
Officer
Dr. Rajesh Kapoor
Chief of Quality
Annual Report 2016-17 Jubilant Life Sciences Limited45Annual Report 2016-17 Jubilant Life Sciences Limited45
Chairmen's Message
Hari S Bhartia
Co-Chairman and Managing Director
Shyam S Bhartia
Chairman
Annual Report 2016-17 Jubilant Life Sciences Limited45Annual Report 2016-17 Jubilant Life Sciences Limited45
Chairmen's Message
Dear Fellow Shareholders,
We are pleased to announce that the Company has reported highest ever revenue and profits in FY 2017. The differentiated business model focusing on Specialty Pharmaceuticals - Injectables has enabled us to deliver exceptional results and build a strong base for growth in Pharmaceuticals. The Company has generated strong operating cash flow, which enabled reduction of debt and is expected to deliver better results going forward. Our focus is to strengthen the balance sheet, invest in strategic opportunities without increasing debt levels and build strong pipeline or products across our businesses. India continues to be the fastest growing economy globally and is expected to grow by 7.2% in FY 2017- 18 as per projections of the International Monetary Fund. This growth is expected to further accelerate to above 8% in the medium term due to implementation of structural reforms, including the transformative GST regime under the current government. According to Evaluate Pharma, the global pharmaceuticals market is expected to grow at 6.3% Compound Annual Growth Rate (CAGR) to US$ 1.12 trillion by 2022. The growth of complex therapeutic areas is projected to outpace the growth of the overall pharmaceutical market, emphasising the importance of increased R&D in the value chain. Global agriculture, on the other hand, has faced some challenges in the last few years but is likely to see a better demand this year for crop protection chemicals in terms of volume as per a report by Federation of IndianChambers of Commerce and Industry (FICCI).
Business Objectives
We are an integrated global pharmaceutical and life sciences Company present across the entire pharmaceutical value chain and take pride in our positioning as one-stop-shop in the glo bal pharmaceutical and life sciences industry, supplying products and services to customers in over100 countries. Our diversified businesses are segmented
in three major verticals namely Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions. Each of these segments is professionally managed by its separate management teams headed by respective CEOs. As a responsible corporate citizen, we are committed to safeguarding the environment and maintaining a triple bottom line approach of sustainability through delivering a high social, environmental and economic performance. The Pharmaceuticals segment is engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile and Non Sterile products through 6 US FDA approved facilities in India, US and Canada. Our success in this segment is based on several key strengths including an innovative productportfolio in specialty injectables with high entry barriers and limited competition, strong R&D capabilities to back
a differentiated pipeline of products, global competitive edge due to low cost from vertically integrated operations, market leadership in key products and business segments, de-risked business model with low concentration risk and a consistent track record of regulatory approvals. As of March 31, 2017, the Company has a total of 922 filings across geographies. Of this, 710 filings have been approved while 212 filings are pending approval.